BRAF and RAS mutations activate the MAPK signaling pathway in thyroid cancer, inducing the expression of phosphorylated ERK1/2, JNK, and P38 kinase, amplifying oncogenicity [3]. This evidence concerns the gene BRAF and thyroid cancer.